RxDoctor Payments Data

Chigolum Eze, MD

Neurology · El Paso, TXNPI 1366649279

Payments from drug & device makers

$3,814in general payments, 2019–2025

Across 35 payments — averaging $108.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • EMD Serono, Inc.$2K
  • Medtronic$1K
  • Novartis$140
  • Eisai Inc.$125
  • AstraZeneca$122
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$112
  • plus $322 from 8 others

What the payments were for

  • Consulting fees$1,80047%
  • Travel & lodging$53514%
  • Food & beverage$1,35736%
  • Education$1223%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,814 in reported general payments places this provider in the 50th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas

Medicare billing

Part B allowed, 2024
$428,291
Medicare patients
549
Services billed
10,484

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SolirisEculizumab12$574,540
Kesimpta PenOfatumumab23$226,028
BotoxOnabotulinumtoxina146$207,346
EpidiolexCannabidiol (Cbd)36$171,636
Aimovig AutoinjectorErenumab-Aooe173$141,089
Emgality PenGalcanezumab-Gnlm170$126,338
BriviactBrivaracetam41$81,952
Nurtec OdtRimegepant Sulfate45$66,134
XcopriCenobamate49$65,443
GlatopaGlatiramer Acetate12$55,114
NeuproRotigotine33$40,751
Memantine Hcl1,497$34,961
Glatiramer Acetate12$25,877
Levetiracetam565$17,455
RytaryCarbidopa/Levodopa29$16,314

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaSoliris$122$574,54012 claims
UCB, Inc.Briviact, Neupro, Vimpat, Nayzilam$15$151,481108 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,246 neurology providers in Texas.

Other neurology in El Paso

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →